Several clinical biomarkers, which serve as reproducible as well as quantitative tools to assess therapeutic efficacy during anti-TNF therapy, have been previously investigated in IBD patients, including C-reactive proteins, faecal calprotectins, and anti-TNF drug levels [9]. This evidence concerns the gene TNF and inflammatory bowel disease.